Compare Stocks: IOVA, EXEL, BMRN, and HALO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$64.16 -1.7%	$61.50	$49.26 ▼ $70.98	$12.42B	0.24	2.06 million shs	353,635 shs
EXEL Exelixis	$54.32 -1.7%	$54.52	$33.76 ▼ $57.57	$13.46B	0.44	2.66 million shs	374,173 shs
HALO Halozyme Therapeutics	$104.91 -1.9%	$86.27	$61.22 ▼ $109.66	$11.91B	0.85	1.86 million shs	496,213 shs
IOVA Iovance Biotherapeutics	$8.02 -2.9%	$5.39	$1.76 ▼ $9.36	$3.63B	0.71	15.66 million shs	3.99 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	-0.49%	-3.53%	+5.19%	+13.96%	+11.30%
EXEL Exelixis	-1.50%	+2.92%	-2.21%	+9.47%	+43.50%
HALO Halozyme Therapeutics	-0.13%	+0.75%	+28.14%	+60.69%	+46.11%
IOVA Iovance Biotherapeutics	+2.23%	-8.12%	+75.74%	+101.46%	+241.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$64.16 -1.7%	$61.50	$49.26 ▼ $70.98	$12.42B	0.24	2.06 million shs	353,635 shs
EXEL Exelixis	$54.32 -1.7%	$54.52	$33.76 ▼ $57.57	$13.46B	0.44	2.66 million shs	374,173 shs
HALO Halozyme Therapeutics	$104.91 -1.9%	$86.27	$61.22 ▼ $109.66	$11.91B	0.85	1.86 million shs	496,213 shs
IOVA Iovance Biotherapeutics	$8.02 -2.9%	$5.39	$1.76 ▼ $9.36	$3.63B	0.71	15.66 million shs	3.99 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	-0.49%	-3.53%	+5.19%	+13.96%	+11.30%
EXEL Exelixis	-1.50%	+2.92%	-2.21%	+9.47%	+43.50%
HALO Halozyme Therapeutics	-0.13%	+0.75%	+28.14%	+60.69%	+46.11%
IOVA Iovance Biotherapeutics	+2.23%	-8.12%	+75.74%	+101.46%	+241.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMRN BioMarin Pharmaceutical	2.75	Moderate Buy	$88.79	38.15% Upside
EXEL Exelixis	2.30	Hold	$50.07	-8.00% Downside
HALO Halozyme Therapeutics	2.62	Moderate Buy	$91.20	-13.22% Downside
IOVA Iovance Biotherapeutics	2.45	Hold	$8.89	10.42% Upside

Current Analyst Ratings Breakdown

Latest IOVA, EXEL, BMRN, and HALO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	BMRN BioMarin Pharmaceutical	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$88.00
8/24/2026	IOVA Iovance Biotherapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$7.00 ➝ $10.00
8/20/2026	IOVA Iovance Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$4.00 ➝ $7.00
8/19/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$98.00
8/18/2026	EXEL Exelixis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$54.00
8/18/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/18/2026	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$60.00 ➝ $59.00
8/18/2026	EXEL Exelixis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$54.00
8/18/2026	IOVA Iovance Biotherapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$10.00 ➝ $11.00
8/17/2026	BMRN BioMarin Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$82.00 ➝ $88.00
8/17/2026	BMRN BioMarin Pharmaceutical	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$105.00 ➝ $111.00

(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMRN BioMarin Pharmaceutical	$3.22B	3.86	$2.79 per share	23.00	$32.66 per share	1.97
EXEL Exelixis	$2.32B	5.81	$2.94 per share	18.53	$7.44 per share	7.31
HALO Halozyme Therapeutics	$1.40B	8.54	$4.68 per share	22.44	$1.26 per share	83.40
IOVA Iovance Biotherapeutics	$263.50M	13.84	N/A	N/A	$1.62 per share	4.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	173.70	11.90	0.47	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	17.11	14.63	1.67	35.33%	42.17%	31.76%	11/3/2026 (Estimated)
HALO Halozyme Therapeutics	$316.89M	$3.35	31.37	11.35	0.43	24.86%	260.98%	23.91%	11/2/2026 (Estimated)
IOVA Iovance Biotherapeutics	-$390.98M	-$0.73	N/A	N/A	N/A	-89.11%	-40.51%	-31.65%	11/5/2026 (Estimated)

Latest IOVA, EXEL, BMRN, and HALO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million
8/6/2026	Q2 2026	IOVA Iovance Biotherapeutics	-$0.1335	-$0.11	+$0.0235	-$0.11	$87.83 million	$198.63 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
EXEL Exelixis	N/A	3.46	3.38
HALO Halozyme Therapeutics	13.50	2.71	2.31
IOVA Iovance Biotherapeutics	N/A	4.34	3.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMRN BioMarin Pharmaceutical	98.71%
EXEL Exelixis	85.27%
HALO Halozyme Therapeutics	97.79%
IOVA Iovance Biotherapeutics	77.03%

Insider Ownership

Company	Insider Ownership
BMRN BioMarin Pharmaceutical	0.68%
EXEL Exelixis	2.60%
HALO Halozyme Therapeutics	2.50%
IOVA Iovance Biotherapeutics	7.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
HALO Halozyme Therapeutics	390	113.50 million	110.66 million	Optionable
IOVA Iovance Biotherapeutics	500	452.97 million	417.64 million	Optionable

IOVA, EXEL, BMRN, and HALO Headlines

Recent News About These Companies

What is Zacks Research's Estimate for IOVA Q3 Earnings?

August 28 at 7:11 AM | marketbeat.com

Palo Alto Investors LP Acquires Shares of 5,296,209 Iovance Biotherapeutics, Inc. $IOVA

August 28 at 6:31 AM | marketbeat.com

Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves

August 27 at 11:51 AM | zacks.com

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

August 27 at 5:31 AM | zacks.com

Ieq Capital LLC Invests $1.22 Million in Iovance Biotherapeutics, Inc. $IOVA

August 27 at 5:03 AM | marketbeat.com

Deutsche Bank AG Invests $3.56 Million in Iovance Biotherapeutics, Inc. $IOVA

August 27 at 3:37 AM | marketbeat.com

Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Raised to $10.00

August 27 at 1:46 AM | americanbankingnews.com

5 Biotech Stocks Worth Adding to Your Portfolio Now

August 26 at 11:20 AM | zacks.com

ADAR1 Capital Management LLC Makes New Investment in Iovance Biotherapeutics, Inc. $IOVA

August 26 at 3:20 AM | marketbeat.com

Iovance Biotherapeutics (NASDAQ:IOVA) Upgraded at TD Cowen

August 25 at 6:59 AM | marketbeat.com

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of "Hold" by Brokerages

August 25 at 2:13 AM | marketbeat.com

Portland Investment Counsel Inc. Acquires Shares of 130,000 Iovance Biotherapeutics, Inc. $IOVA

August 24, 2026 | marketbeat.com

Iovance Biotherapeutics stock is trending Friday: What's going on?

August 22, 2026 | msn.com

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

August 21, 2026 | globenewswire.com

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 5.8% - Here's Why

August 21, 2026 | marketbeat.com

Iovance Biotherapeutics (NASDAQ:IOVA) Trading 11% Higher After Analyst Upgrade

August 21, 2026 | americanbankingnews.com

Here's Why Iovance Biotherapeutics (IOVA) is a Great Momentum Stock to Buy

August 20, 2026 | zacks.com

Iovance Biotherapeutics: Breakout Quarter, Catalysts Ahead, And Competitor Updates

August 20, 2026 | seekingalpha.com

Iovance Biotherapeutics (NASDAQ:IOVA) Marks Major Market Shift

August 20, 2026 | kalkinemedia.comK

Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 12-Month High - What's Next?

August 20, 2026 | marketbeat.com

Mizuho Increases Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $11.00

August 20, 2026 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA, EXEL, BMRN, and HALO Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

$64.16 -1.13 (-1.73%)

As of 12:45 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Exelixis NASDAQ:EXEL

$54.32 -0.94 (-1.70%)

As of 12:45 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Halozyme Therapeutics NASDAQ:HALO

$104.91 -2.01 (-1.88%)

As of 12:45 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Iovance Biotherapeutics NASDAQ:IOVA

$8.02 -0.24 (-2.91%)

As of 12:45 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IOVA, EXEL, BMRN, and HALO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IOVA, EXEL, BMRN, and HALO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IOVA, EXEL, BMRN, and HALO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA, EXEL, BMRN, and HALO Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

Halozyme Therapeutics NASDAQ:HALO

Iovance Biotherapeutics NASDAQ:IOVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IOVA, EXEL, BMRN, and HALO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IOVA, EXEL, BMRN, and HALO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IOVA, EXEL, BMRN, and HALO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA, EXEL, BMRN, and HALO Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

Halozyme Therapeutics NASDAQ:HALO

Iovance Biotherapeutics NASDAQ:IOVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools